12 completed. 12 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 12 |
| Phase 1 | 4 | Completed 4 |
Follow Pseudomonas Aeruginosa: new trials by email Literature Review of Pseudomonas Aeruginosa trials Research Report on Pseudomonas Aeruginosa
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PMT for MDRO Decolonization PMT - Multidrug Resistant Bacterial Infection, Enterobacteriaceae Infections | Phase 2 | Completed | University of Pennsylvania | 32 | 2024-08-19 | 2026-09-24 |
| A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection RSP-1502, Tobramycin inhalation solution - Cystic Fibrosis Lung, Respiratory Infections, Recurrent, Chronic | Phase 1 / Phase 2 | Completed | Respirion Pharmaceuticals Pty Ltd | 71 | 2024-04-01 | 2026-06-25 |
| Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection AP-PA02, Placebo - Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa | Phase 2 | Completed | Armata Pharmaceuticals, Inc. | 48 | 2023-01-10 | 2026-01-05 |
| Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis AP-PA02, Placebo - Cystic Fibrosis, Pseudomonas Aeruginosa | Phase 1 / Phase 2 | Completed | Armata Pharmaceuticals, Inc. | 29 | 2020-12-22 | 2024-01-31 |
| Safety and Efficacy Study of Ftortiazinon in the Treatment of Patients With Complicated Urinary Tract Infections Caused by P. Aeruginosa Ftortiazinon (tablets 300 mg) 1/2 dose +placebo+ Maxipim, Ftortiazinon (tablets 300 mg) full dose + Maxipim, placebo+Maxipim - Patients With Complicated Urinary Tract Infections Caused by P. Aeruginosa, Pseudomonas Aeruginosa | Phase 2 | Completed | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | 777 | 2018-10-17 | 2025-06-22 |
| Effort to Prevent Nosocomial Pneumonia Caused by Pseudomonas Aeruginosa in Mechanically Ventilated Subjects MEDI3902, Placebo - Pseudomonas Aeruginosa | Phase 2 | Completed | MedImmune LLC | 188 | 2016-03-25 | 2021-02-04 |
| Sino-nasal Inhalation of Colistin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization Colistin - Cystic Fibrosis, Pseudomonas Aeruginosa | Phase 2 | Completed | University of Jena | 10 | 2009-12-01 | 2013-03-21 |
| Nasal Inhalation of Tobramycin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization Tobramycin (Gernebcin®) - Cystic Fibrosis, Pseudomonas Aeruginosa | Phase 2 | Completed | University of Jena | 9 | 2008-10-01 | 2014-12-04 |
| Pilot Trial of KB001 in Mechanically-Ventilated Patients Colonized With Pseudomonas Aeruginosa KB001, Placebo - Pseudomonas Aeruginosa, Ventilator Associated Pneumonia | Phase 1 / Phase 2 | Completed | Humanigen, Inc. | 36 | 2008-04-01 | 2009-07-31 |
| Anti-Inflammatory Pulmonal Therapy of CF-Patients With Amitriptyline and Placebo amitriptyline - Cystic Fibrosis, Infection | Phase 2 | Completed | University Hospital Tuebingen | 18 | 2006-10-01 | 2007-08-13 |
| Anti-pseudomonas IgY to Prevent Infections in Cystic Fibrosis Anti-pseudomonas IgY gargle - Cystic Fibrosis, Infection | Phase 1 / Phase 2 | Completed | Immunsystem AB | 14 | 2003-11-01 | 2016-09-01 |
| Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa Infection Aztreonam for Inhalation (AI), Placebo - Cystic Fibrosis, CF | Phase 2 | Completed | Gilead Sciences | 105 | 2003-06-01 | 2010-01-26 |
Pseudomonas Infections (12) · Cystic Fibrosis (7) · Infections (2) · Bronchiolitis Obliterans Syndrome (1) · Enterobacteriaceae Infections (1) · Pneumonia (1) · Pneumonia, Ventilator-Associated (1) · Recurrence (1) · Respiratory Tract Infections (1) · Urinary Tract Infections (1)
Bacterial Infections (12) · Bacterial Infections and Mycoses (12) · Gram-Negative Bacterial Infections (12) · Infections (10) · Lung Diseases (9) · Respiratory Tract Diseases (9) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (7) · Digestive System Diseases (7) · Genetic Diseases, Inborn (7) · Infant, Newborn, Diseases (7) · Pancreatic Diseases (7) · Disease Attributes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Respiratory Tract Infections (2)
Amitriptyline (1) · Aztreonam (1) · Colistin (1) · Immunotherapy (1) · Inhalation (1) · Tablets (1) · Tobramycin (1) · gremubamab (1)
Armata Pharmaceuticals, Inc. (2) · University of Jena (2) · Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation (1) · Gilead Sciences (1) · Humanigen, Inc. (1) · Immunsystem AB (1) · MedImmune LLC (1) · Respirion Pharmaceuticals Pty Ltd (1) · University Hospital Tuebingen (1) · University of Pennsylvania (1)
United States (6) · Germany (3) · France (2) · Australia (1) · Austria (1) · Belgium (1) · Croatia (1) · Czechia (1) · Greece (1) · Hungary (1) · Ireland (1) · Israel (1) · Portugal (1) · Russia (1) · Spain (1)
Jochen Mainz, M.D. (2) · Alexander Mangushlo, MD (1) · Alexander Shvets, MD (1) · Andrey Gorelov, MD (1) · Annika Hollsing, MD, PhD (1) · Ashot Yesayan, MD (1) · Brendan J Kelly (1) · Dmitry Gorelov, MD (1) · Elena Matevosyan, MD (1) · George Retsch-Bogart, MD (1) · Grigory Arutunov, MD (1) · Igor Shormanov, MD (1) · Ivan Palagin, MD (1) · Joachim Reithmueller, Dr. (1) · Lev Sinelnikov, MD (1)